BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8678507)

  • 1. [Impact of rapid advancement of international standardization on technical requirements for new drug registration].
    Kurokawa T
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):509-16. PubMed ID: 8678507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of anti-cancer drugs under new renewed GCP--from the viewpoint of drug development company developer].
    Ueno T; Kobayashi T; Inoue K; Yanagi Y; Yamada Y
    Gan To Kagaku Ryoho; 1998 Apr; 25(5):663-70. PubMed ID: 9571963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Participation to international registration trials--from the investigator's standpoint].
    Ohtsu A
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):297-300. PubMed ID: 17301548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Why multi-national clinical trials now?--Industry perspective].
    Miki S
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):293-6. PubMed ID: 17301547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Operational aspect of participation in the multi-national clinical trials from the foreign pharmaceutical company's standpoint].
    Namazu K
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):328-30. PubMed ID: 17301556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Present strategy for new drug development in the USA].
    Shimada Y
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():315-24. PubMed ID: 7986110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status and problems in development of molecular target agents for gastrointestinal malignancy in Japan.
    Boku N
    Jpn J Clin Oncol; 2010 Mar; 40(3):183-7. PubMed ID: 20047861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Globalization of clinical trials].
    Akaza H; Fukuoka M; Ohtsu A; Usami M; Ikeda T; Aiba K; Isonishi S; Ohashi Y; Saijo N; Sone S; Tsukagoshi S; Tsuruo T; Kato M; Mikami O; Dong RP; von Euler M; Blackledge G; Stribling D
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):555-65. PubMed ID: 12722692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in the clinical development requirements for the marketing authorization of new medicines in southeast Asia.
    Kudrin A
    J Clin Pharmacol; 2009 Mar; 49(3):268-80. PubMed ID: 19168433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan].
    Andoh M; Fujiwara Y; Shimada Y
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):1015-9. PubMed ID: 16878363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tuberculosis and its control--lessons from the past and future prospect].
    Shimao T
    Kekkaku; 2005 Jun; 80(6):481-9. PubMed ID: 16130906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beware the Medical-Industrial Complex.
    Stevens CW; Glatstein E
    Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.